BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24021662)

  • 1. Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease.
    Camboni M; Wang CM; Miranda C; Yoon JH; Xu R; Zygmunt D; Kaspar BK; Martin PT
    Neurobiol Dis; 2014 Feb; 62():31-43. PubMed ID: 24021662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.
    Wang CM; Devries S; Camboni M; Glass M; Martin PT
    Neurobiol Dis; 2010 Sep; 39(3):409-22. PubMed ID: 20493257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
    Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
    J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.
    Maier M; Seabrook TJ; Lazo ND; Jiang L; Das P; Janus C; Lemere CA
    J Neurosci; 2006 May; 26(18):4717-28. PubMed ID: 16672644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages.
    Asuni AA; Boutajangout A; Scholtzova H; Knudsen E; Li YS; Quartermain D; Frangione B; Wisniewski T; Sigurdsson EM
    Eur J Neurosci; 2006 Nov; 24(9):2530-42. PubMed ID: 17100841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization of Tg-APPswe/PSEN1dE9 mice with Aβ3-10-KLH vaccine prevents synaptic deficits of Alzheimer's disease.
    Meng Y; Ding L; Zhang H; Yin W; Yan Y; Cao Y
    Behav Brain Res; 2017 Aug; 332():64-70. PubMed ID: 28577919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.
    Sigurdsson EM; Knudsen E; Asuni A; Fitzer-Attas C; Sage D; Quartermain D; Goni F; Frangione B; Wisniewski T
    J Neurosci; 2004 Jul; 24(28):6277-82. PubMed ID: 15254082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
    Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
    ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease.
    Minami SS; Sidahmed E; Aid S; Shimoji M; Niikura T; Mocchetti I; Rebeck GW; Prendergast JS; Dealwis C; Wetzel R; Bosetti F; Matsuoka Y; Hoe HS; Turner RS
    J Neuroinflammation; 2010 Sep; 7():57. PubMed ID: 20920207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice.
    Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP
    Neurosci Lett; 2016 Nov; 634():1-6. PubMed ID: 27693663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Abeta immunogens: is shorter better?
    Lemere CA; Maier M; Peng Y; Jiang L; Seabrook TJ
    Curr Alzheimer Res; 2007 Sep; 4(4):427-36. PubMed ID: 17908047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice.
    Petrushina I; Ghochikyan A; Mkrtichyan M; Mamikonyan G; Movsesyan N; Ajdari R; Vasilevko V; Karapetyan A; Lees A; Agadjanyan MG; Cribbs DH
    J Neuroinflammation; 2008 Sep; 5():42. PubMed ID: 18823564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines for Alzheimer's disease: how close are we?
    Janus C
    CNS Drugs; 2003; 17(7):457-74. PubMed ID: 12751917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies.
    Dai CL; Chen X; Kazim SF; Liu F; Gong CX; Grundke-Iqbal I; Iqbal K
    J Neural Transm (Vienna); 2015 Apr; 122(4):607-17. PubMed ID: 25233799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Aβ3-10-KLH vaccine reduced Alzheimer's disease-like pathology and had a sustained effect in Tg-APPswe/PSEN1dE9 mice.
    Meng Y; Ding L; Zhang HY; Yin WC; Yan Y; Cao YP
    Brain Res; 2017 Oct; 1673():72-77. PubMed ID: 28779977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.
    Adolfsson O; Pihlgren M; Toni N; Varisco Y; Buccarello AL; Antoniello K; Lohmann S; Piorkowska K; Gafner V; Atwal JK; Maloney J; Chen M; Gogineni A; Weimer RM; Mortensen DL; Friesenhahn M; Ho C; Paul R; Pfeifer A; Muhs A; Watts RJ
    J Neurosci; 2012 Jul; 32(28):9677-89. PubMed ID: 22787053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy.
    Wang A; Das P; Switzer RC; Golde TE; Jankowsky JL
    J Neurosci; 2011 Mar; 31(11):4124-36. PubMed ID: 21411653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine efficacy of transcutaneous immunization with amyloid β using a dissolving microneedle array in a mouse model of Alzheimer's disease.
    Matsuo K; Okamoto H; Kawai Y; Quan YS; Kamiyama F; Hirobe S; Okada N; Nakagawa S
    J Neuroimmunol; 2014 Jan; 266(1-2):1-11. PubMed ID: 24315156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.
    Petrushina I; Ghochikyan A; Mktrichyan M; Mamikonyan G; Movsesyan N; Davtyan H; Patel A; Head E; Cribbs DH; Agadjanyan MG
    J Neurosci; 2007 Nov; 27(46):12721-31. PubMed ID: 18003852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.